Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety ...
Business Recorder

Buying returns to bourse, KSE-100 up nearly 2,200 points in early trade

On Monday, the PSX witnessed a sharp sell-off as the benchmark KSE-100 Index plunged, as investors remained wary due to ...

Johnson & Johnson-Protagonist Therapeutics partnered new psoriasis pill wins FDA nod, shakes up competition with AbbVie

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor ...
Business Recorder

Volatility at bourse, KSE-100 closes above 150,000 level

A volatile trading session was observed at the Pakistan Stock Exchange (PSX) with the benchmark KSE-100 Index swinging both ...